
Alamar Biosciences' NULISA platform featured in 140+ studies at AAIC 2026, advancing blood-based Alzheimer's biomarker detection.
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...



